



**Remarks**

In the Communication dated 27 December 2007, restriction to one of the independent and distinct species of compounds represented by formula 1.

|          |                      |   |
|----------|----------------------|---|
| Group 1; | Claims 1, 3-15;      | Drawn to benzothiphene compounds of core structure A. See below |
| Group 2; | Claim 2;             | Drawn to benzothiphene compounds of core structure B.           |
| Group 3; | Claims 16-17, 20-22; | Drawn to pharmaceutical methods of use of compounds (A).        |
| Group 4; | Claims 16-17, 20-22; | Drawn to pharmaceutical methods of use of compounds (B).        |

**Core Structure A****Core Structure B**

In response, the Applicants elect the prosecute claims 1, and 23-15 of Group I compounds (A) without traverse.

In addition upon indication of allowable subject matter, rejoinder of the Group 2 claims will be sought.

The Examiner is invited to contact the undersigned attorney by telephone if there are any questions about this Submission or other issues that may be resolved in that fashion.

Respectfully submitted,

/James B. Myers/  
James B. Myers  
Attorney for Applicants  
Registration No. 42,021  
Phone: 317-276-0755

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288  
28 January 2008